Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

B-MS, Syngene Extend Research Collaboration

Published: Wednesday, June 04, 2014
Last Updated: Wednesday, June 04, 2014
Bookmark and Share
Companies announce a five-year extension of their drug discovery and development collaboration in India.

Since 2007, Bristol-Myers Squibb has been working with Syngene International and its corporate parent, Biocon Ltd., to develop integrated capabilities in medicinal and process chemistry, biology, biotechnology, biomarkers, drug metabolism and pharmacokinetics, analytical research, and pharmaceutical development at the Biocon Bristol-Myers Squibb Research Center (BBRC) in Bangalore. 

The U.S.-India collaboration has produced six drug candidates for further study and also helped Bristol-Myers Squibb reduce the time and costs associated with advancing new compounds to first-in-human studies. One drug candidate currently in clinical trials was discovered at BBRC and early nonclinical development work done at BBRC has enabled most of Bristol-Myers Squibb’s small molecule assets to advance to later stages of development over the last five years. 

Commenting on the new agreement, Peter Bains, Director, Syngene International, said: “We are extremely delighted to extend our discovery and development partnership with Bristol-Myers Squibb for another five years. This extension reflects the strength of our existing collaboration which has delivered many successful outcomes. The scope of Syngene’s engagement has expanded to encompass a broad range of integrated service offerings across the drug discovery and development continuum. We remain committed to supporting Bristol-Myers Squibb in their pursuit of developing new and innovative medicines for the future.” 

Francis Cuss, Executive Vice President and Chief Scientific Officer, Bristol-Myers Squibb, said: “I am excited about the opportunity to continue our highly productive collaboration with Biocon and Syngene. The BBRC has supported the nonclinical development of a large proportion of our small-molecule portfolio assets since its inception, and is a premier example of the high-quality innovative drug hunting that is taking place in India today. 

Bristol-Myers Squibb and Syngene jointly developed the BBRC at Biocon Park in Bangalore. Over the years, BBRC has become Bristol-Myers Squibb’s largest research and development center outside the United States, housing more than 400 scientists.  

Financial terms were not disclosed.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Bristol-Myers Squibb to Acquire Padlock Therapeutics
Expands BMS immunoscience pipeline with potentially transformational approach to treating rheumatoid arthritis and other autoimmune diseases.
Thursday, March 24, 2016
Scientific News
Parkinson's Disease Linked to Microbiome
Scientists have discovered a link between intestinal bacteria and Parkinson's disease.
Making Personalized Medicine a Reality
Groundbreaking technique developed at McMaster University is helping to pave the way for advances in personalized medicine.
Top 10 Life Science Innovations of 2016
2016 has seen the release of some truly innovative products. To help you digest these developments, The Scientist have listed their top picks for the year.
Possible Treatment for Rare Vascular Disease
Researchers manage to reverse hereditary haemorrhagic telangiectasia in mice, if successful in humans it could lead to improved treatment for the disease.
Cracking the Code of a Deadly Virus
Researchers have exploited weaknesses in VEEV's genetic code, creating a far less deadly variant.
New Compound to Reduce Tumor Growth
Researchers at Stanford found that a new cell surface receptor they created is effective at inhibiting cancer growth in mice.
Vaccination Against UTIs
Researchers have successfully vaccinated mice against E.coli growth in the bladder and kidneys.
Toxoplasma’s Balancing Act Explained
Parasite’s method of rewiring our immune response leads to novel tool for drug tests.
Common Virus Helps Fight Liver Cancer
Reovirus, a cause of childhood colds, stimulates the immune system to kill cancerous cells.
Long-Lasting Pill to Fight Malaria
An ultra-long acting pill has been developed to offer a new hope in eliminating malaria.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!